Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6476259

FCCCCN1CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.43
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SIGMAR1 Q99720 2/20 0.39
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ITGB3 P05106 2/20 0.35
ITGA2B P08514 2/20 0.35
PKM P14618 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1401787 0.88 PKM (0.38) CXCR4CHRM2CHRM4CHRM5CHRM1
Trifluoroacetic Acid SCHEMBL1401786 0.88 PKM (0.38) CXCR4CHRM2CHRM4CHRM5CHRM1
Trifluoroacetic Acid SCHEMBL29384411 0.87 CXCR4 (0.43) CXCR4CHRM2CHRM4CHRM5CHRM1
Trifluoroacetic Acid SCHEMBL27584030 0.85 GNAO1 (0.48) CXCR4ALDH1A1KDM4ENPC1RAB9A
Trifluoroacetic Acid SCHEMBL3470280 0.83 ALOX15 (0.41) CXCR4CHRM2CHRM4CHRM5CHRM1
Trifluoroacetic Acid SCHEMBL6477387 0.83 MEN1 (0.45) CHRM2CHRM4CHRM5CHRM1CHRM3
Trifluoroacetic Acid SCHEMBL8438777 0.82 CXCR4 (0.47) CXCR4CHRM2CHRM4CHRM5CHRM1
Trifluoroacetic Acid SCHEMBL22123107 0.79 KDM4E (0.39) CXCR4CHRM2CHRM4CHRM5CHRM1
SCHEMBL13733149 0.78 CXCR4 (0.56) CXCR4CHRM2CHRM4CHRM5CHRM1
Trifluoroacetic Acid SCHEMBL6661048 0.77 MEN1 (0.49) ALDH1A1LMNAKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962911-B2 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2005-11-08 US disclosed
EP-1257553-B1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO LTD (KR) 2004-05-26 EP disclosed
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2003-09-11 US disclosed
EP-1257553-A1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK Chemicals Co., Ltd. (KR) 2002-11-20 EP disclosed
WO-2001060825-A1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO., LTD. (KR) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use CYP2C19, DHPS, SDHA CXCR4 1950/4885CHRM2 4170/4885CHRM4 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.